Tekturna and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Tekturna (aliskiren hemifumarate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Norvasc, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Memory loss when taking Tekturna. It is created by eHealthMe based on reports of 4,498 people who have side effects when taking Tekturna from the FDA, and is updated regularly.

What is Tekturna?

Tekturna has active ingredients of aliskiren hemifumarate. It is often used in high blood pressure. eHealthMe is studying from 4,730 Tekturna users. Check the latest studies of Tekturna.

What is Memory loss?

Memory loss is found to be associated with 2,728 drugs and 4,375 conditions by eHealthMe. Check the latest studies of Memory loss.

On Jul, 11, 2026

4,498 people reported to have side effects when taking Tekturna.
Among them, 51 people (1.13%) have Memory loss.

Among these 51 people:

How long have people been on Tekturna when they have Memory loss? *

What is the gender of people who have Memory loss when taking Tekturna? *

female: 54.9 %
male: 45.1 %

What is the age of people who have Memory loss when taking Tekturna? *

What are other drugs people take besides Tekturna? *

What are other side effects people have besides Memory loss? *

Confusional State: 11 people, 21.57%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 9 people, 17.65%
Headache (pain in head): 8 people, 15.69%
Depression: 8 people, 15.69%
Stress And Anxiety: 8 people, 15.69%
Fatigue (feeling of tiredness): 7 people, 13.73%
Loss Of Consciousness: 7 people, 13.73%
Pain In Extremity: 7 people, 13.73%
Chest Pain: 7 people, 13.73%
Back Pain: 6 people, 11.76%

What are the existing conditions these people have? *

High Blood Cholesterol: 6 people, 11.76%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 5.88%
Agitation (state of anxiety or nervous excitement): 2 people, 3.92%
Pain: 2 people, 3.92%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 3.92%
Nausea (feeling of having an urge to vomit): 2 people, 3.92%
Osteoporosis (bones weak and more likely to break): 2 people, 3.92%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 3.92%
Stress And Anxiety: 2 people, 3.92%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 1.96%

* Approximation only. Some reports may have incomplete information.

Do you take Tekturna and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tekturna:

Tekturna (4,730 reports)

Memory loss treatments and more:

Memory loss (244,444 reports)

Browse all side effects of Tekturna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,728 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,375 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aliskiren hemifumarate (the active ingredients of Tekturna) and Tekturna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.